🧬 Barry Ticho - Part 3 | Lessons From Rigorous Drug Development | Industry vs. Academic Research Standards | A Patient-Centered Approach to Clinical Trials | How RNA is Shaping Modern Medicine

Part 3 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas. Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.